Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

GenesisCare and the University of Oxford establish innovative 10-year research partnership to improve diagnosis and care for people with cancer.

3D rendition of MRI machine

Today GenesisCare and the University of Oxford’s Department of Oncology announce the launch of an exclusive 10-year partnership to enhance access to the latest technology in medicine to improve diagnosis, management, and treatment of cancer. A first priority of the partnership will be the installation and use of a Magnetic Resonance Linear Accelerator (MR LinAc) at GenesisCare’s centre in Oxford, along with research into new clinical planning techniques.

The MR LinAc will be used both for research and the treatment of patients in the Oxford area, locating and measuring cancer in real-time and adjusting radiation delivery to changing tumours with unrivalled accuracy. This technology has the potential to drastically change the patient treatment experience and the way in which treatment planning and delivery is conducted.

Read more (Department of Oncology website)

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Athena Swan Gold Award success for Nuffield Department of Primary Care Health Sciences

The award reflects the Department’s commitment to representation, progression and success for all. It acknowledges the innovative policies and practices developed across the department and the detailed action plans for improvement.

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

Multiple Debilitating Pains – New global study shows the experience of Endometriosis is rooted in a person’s genetics

Researchers at the University of Oxford in collaboration with 25 teams across the world have published the largest study to date of the genetic basis of endometriosis.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.